ORGANIZATION
Industry Leaders Issue Statements on FY2020 Reform Package; Improved PMP Criteria Given Certain Credit
Pharma industry chieftains on December 20 issued their statements for a package of reform plans approved on the day for the FY2020 drug pricing reform next April, with proposed revisions to the price maintenance premium (PMP) credited as “a certain…
To read the full story
Related Article
- Japan Panel Hammers Out FY2020 Drug Pricing Reform
December 20, 2019
ORGANIZATION
- BCG’s Takeda Questions Conditional Pricing for Regenerative Medicines
March 25, 2026
- Industry Groups Push Mindset Shift to Streamline Japan’s Clinical Trials
March 24, 2026
- FY2027 Off-Year Drug Price Revision Already Decided: Kenporen Director
March 24, 2026
- FPMAJ Calls for Drug Price Hike, End to Off-Year Revisions in FY2026 Plan
March 23, 2026
- JPMA Names Shionogi’s Go Takahashi as Managing Director
March 23, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





